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Abstract
Background: As the prevalence of hip pathology in the younger athletic population rises, the medical community
continues to investigate effective intervention options. Femoracetabular impingement is the morphologically
abnormal articulation of the femoral head against the acetabulum, and often implicated in pre-arthritic hip
conditions of musculoskeletal nature. Arthroscopic surgical decompression and non-surgical rehabilitation programs
focused on strengthening and stability are common interventions. However, they have never been directly
compared in clinical trials.
The primary purpose of this study will be to assess the difference in outcomes between these 2 commonly utilized
interventions for femoracetabular impingement.
Methods: The study will be a single site, non-inferiority, randomized controlled trial comparing two different
treatment approaches (surgical and nonsurgical) for FAI. The enrollment goal is for a total of 80 subjects with a
diagnosis of Femoracetabular impingement that are surgical candidates and have failed 6 weeks of conservative
treatment. This will be a convenience sample of consecutive patients that are Tricare beneficiaries and seeking care
at Madigan Army Medical Center. Patients that meet the criteria will be screened, provide written consent before
enrollment, and then randomized into one of two arms (Group I = hip arthroscopy, Group II = physical therapy).
Group I will undergo hip arthroscopy with or without labral repair. Group II will follow an impairment based
physical therapy program consisting of 2 sessions per week for 6 weeks. The primary outcome will be the Hip
Outcome Score and secondary measures will include the International Hip Outcome Tool and the Global Rating of
Change. Measures will be taken at baseline, 6 months, 1 and 2 years. Hip-related healthcare utilization between
both groups will also be assessed at the end of 2 years.
Discussion: The current evidence to support both surgical and conservative interventions for femoroacetabular
impingement is based on low-level research. To date, none of these interventions have been directly compared in
a randomized clinical trial. Clinical trials are needed to help establish the value of these interventions in the
management of femoracetabular impingement and to help define appropriate clinical pathways.
Trial registration: NCT01993615 30 October 2013.
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Background
Femoracetabular impingent (FAI) consists of abnormal
morphology of the acetabulum and/or proximal femur.
This can result in cartilage injury as well as tears to the ac-
etabular labrum [1–3]. The type of abnormal morphology
is often separated into three categories, Cam (femoral
neck), Pincer (acetabulum) and combined based on where
the abnormality lies. This condition is encountered more
commonly in younger active patients, and especially
males. Some think it plays a role in the development of
osteoarthritis, placing it within a pre-arthritic hip disease
(PAHD) classification.
Because the diagnosis is strongly based on changes in
bone morphology, radiographic imaging plays a significant
role in the diagnosis, prognosis and surgical treatment of
FAI. Common radiographic findings thought to aid in the
diagnosis include measures of acetabular retroversion
(crossover sign [1], ischial spine sign [2], and posterior
wall sign [3]) and femoral neck angles and morphology
(alpha angle [4], and pistol grip deformity [5]). These mea-
sures also assist with the planning for surgical interven-
tions, and some authors have even linked radiographic
findings with prognosis of FAI, such as the amount of
radiographic joint space narrowing [6]. However, others
studies point out the poor diagnostic accuracy of radio-
graphic findings in the diagnosis of hip pathology, [7] and
the potentially high prevalence of labral tears found in the
asymptomatic population (as high as 73 %) [8, 9]. Others
report very little diagnostic value in some of these same
radiographic signs related to acetabular retroversion
(crossover, ischial, and posterior wall) [10, 11].
This helps bring to light the diagnostic controversy
related to FAI. If many of these radiographic anatomical
variations help guide treatment decisions, but lack validity,
then understanding optimal treatments for FAI becomes
more challenging. The surgical approach focuses on ad-
dressing the anatomical impairments thought to cause the
pathology. It has been referred to as a “hip preserving”
intervention [12], that may potentially mitigate the onset
of degenerative osteoarthritis. However, there is no evi-
dence to suggest that progression of joint degeneration
will not occur beyond what is expected in a morphologic-
ally normal control group [13, 14]. Only cohort-level stud-
ies have been performed to date, and these have reported
favorable outcomes only in the short term [15–17]. Others
caution about the significant variation in reported clinical
and radiographic outcomes after surgery [15]. Zaltz and
colleagues [18] warn that “indications and limits of arth-
roscopy must be carefully defined” and more research is
needed to identify variables associated with failure rates
and poor outcomes. Despite the challenges and contro-
versy related to diagnosis, and lack of clinical trials to sup-
port surgical efficacy, surgery for the correction of FAI in
the U.S. has increased significantly in the recent decade
[9, 10]. This represents an eighteen-fold increase between
1999 and 2009 [11].
Conservative management is typically the precursor to
most elective orthopaedic surgeries. Invasive surgical in-
terventions are usually considered after conservative ap-
proaches have failed. However, there is also a large gap
in the efficacy research of non-surgical interventions for
FAI. Only low quality studies exist, consisting primarily
of case studies and expert opinion [19–22]. Conservative
management can include physical therapy, activity modi-
fication and avoidance of provocative hip positions [22].
There is no research beyond expert opinion to guide
conservative physical therapy approaches to optimal
management of FAI.
At present there are no randomized controlled trials
that have compared surgery to a conservative interven-
tion (e.g., physical therapy) for the treatment of FAI.
Therefore, the primary purpose is to determine if there
is a difference in self-reported functional outcomes be-
tween arthroscopic surgery and a supervised physical
program for patients with FAI out at 2 years. The sec-
ondary aim is to evaluate the differences in hip-related
healthcare utilization and associated costs between sub-
jects in each group during the 2-year period following
treatment.
Methods/design
The study will be a single site, non-inferiority, random-
ized controlled trial comparing two different treatment
approaches (surgical and nonsurgical) for FAI.
Potential subjects will be identified through the stand-
ard referral process to the orthopedic surgery and/or
physical therapy clinic. Patients are referred through the
computerized Composite Healthcare System (CHCS) by
providers within the Madigan Army Healthcare System.
An orthopedic surgeon at Madigan Army Medical
Center (MAMC) will confirm that the patient is a candi-
date for hip arthroscopy prior to being considered for
participation in the study (as outlined in the Inclusion/
Exclusion Criteria). Research investigators and/or re-
search assistants will ensure that potential subjects meet
all inclusion and exclusion criteria prior to consent. All
subjects will provide written informed consent before
participating in the study. The protocol received ethics
approval by the Madigan Army Medical Center Institu-
tional Review Board. All interventions provided in this
study are considered standard of care and could be given
to a patient as part of their treatment plan even if they
were not a part of this study. An ethics review will be
conducted by Madigan Army Medical Center and moni-
tored by the US Army Medical Department Clinical
Investigation Regulatory Office to ensure compliance
with federal regulations for protection of human medical
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research subjects. Participants can request to discon-
tinue the study at any point.
Following consent, the investigators and/or research
personnel will gather demographic information and ob-
jective measures for all subjects. A subject number will be
assigned for each subject; all information collected will in-
clude the subject number only. All subjects will also
complete a Hip Outcome Score (HOS), International Hip
Outcome Tool Score, Global Rating of Change, Self
Motivational Inventory, Pain Body Diagram, pain report
via the Numeric Pain Rating Scale, and the Pain Catastro-
phizing Scale. The primary outcome measure will be the
HOS at 2 years.
Subjects will then be randomized into one of two arms
(Group I =Hip Arthroscopy, Group II = Physical Therapy).
The method of group assignment will be determined via se-
quentially numbered opaque sealed envelopes. To minimize
the risk of predicting the treatment assignment of the next
eligible patient, randomization will be performed in per-
muted blocks of two or four with random variation of the
blocking number. Date of enrollment will be used as the
baseline date for both groups. Surgery will typically be
scheduled within the following 3 months and physical ther-
apy will typically be initiated within 1 to 2 weeks.
Group I will receive arthroscopy surgery. The hip arth-
roscopy will consist of acetabular rim trimming, labral re-
pair or debridement and femoroplasty, all as indicated
based on the surgeon’s clinical judgment with input from
pre-operative imaging, exam findings and intra-operative
findings. Typical surgery time is approximately 2 h in dur-
ation; surgery time may fluctuate up to 60 min depending
on the complexity of the surgery. Hip arthroscopy is typic-
ally a same-day surgery; however subjects may require an
overnight stay at the discretion of the orthopedic surgeon.
This is standard for how a patient would receive this inter-
vention outside of the study.
Following surgery, subjects will be evaluated by a phys-
ical therapist in the MAMC outpatient physical therapy
clinic within 7 days to begin post-operative rehabilitation
(Additional file 1). Typical post-operative rehabilitation is
completed within 6 months following surgery; however
additional care may be required at the discretion of the
physical therapist. Subjects within this group will follow
up with a research investigator and/or research assistant at
MAMC to complete outcome measures following surgery
at 6 month, 1 year and 2 year time periods.
Group II will receive a standardized physical therapy
program that is supervised in the clinic for 6 weeks. Sub-
jects will participate in two 45-min physical therapy visits a
week for 6 weeks, for a total of 12 sessions. The physical
therapy treatment plan will be based on individual impair-
ments identified during the initial evaluation (Additional
file 2). Typical treatment for FAI includes hip mobilizations
(Additional file 3) and therapeutic exercise (Additional files
4 and 5), however other treatment interventions may be
implemented at the discretion of the physical therapist.
After 12 sessions of physical therapy, patients will be
released from treatment. Subjects can follow-up with
their primary care provider for any additional specialty
care referrals, to include orthopedics and physical ther-
apy. Subjects will be analyzed in the groups they were
originally randomized to.
Subjects will follow-up with a research investigator or
research assistant that is unaware of the treament alloca-
tion, in order to complete outcomes measures at 6 month,
1 and 2 year time periods following the initial physical
therapy evaluation.
This will be a single center randomized controlled trial
with sequential enrollment of a convenience sample, with
concealed allocation and blinded outcome assessors. The
independent variable is treatment (physical therapy or
arthroscopic surgery) and time with 4 levels out to 2 years.
We will analyze any potential covariates that may affect
prognosis, to include internal motivation and psychosocial
beliefs using the Self Motivation Inventory scale and the
Pain Catastrophizing Scale. This will be a trial assessing
pragmatic delivery of two common interventions, and will
report results following CONSORT guidelines for prag-
matic trials [23]. The current SPIRIT guidelines for creat-
ing protocols for randomized clinical trials were followed
in deriving the protocol [24]. Figure 1 demonstrates the
flow of subjects through the trial.
Participants
We plan to enroll 80 subjects into this study. Consecu-
tive patients seen in the orthopaedic surgery clinic with
hip pain that meet all inclusion/exclusion criteria will be
offered the opportunity to enroll in the study. Therefore
all subjects will be recruited from within the orthopaedic
surgery service at Madigan Army Medical Center, after
diagnosis and surgical candidacy for FAI has been
established.
Inclusion criteria (must meet all 3)
 Tricare beneficiaries between the ages of 18
and 60
 Must have a clinical diagnosis of FAI and/or labral
pathology confirmed by a combination of all the
following physical examination findings:
○Patient self-report of pain in the anterior hip or groin
○Pain reproduced with passive or active flexion
○Positive FADIR (Flexion Adduction Internal
Rotation) test
○ Subjective relief of pain after intra-articular
injection
Mansell et al. BMC Musculoskeletal Disorders  (2016) 17:60 Page 3 of 9
 Must be a surgical candidate for hip arthroscopy
defined by (must have all 3):
○No less than 2 mm of joint space based on imaging
(CT scan, radiographs and MR arthrogram)
○Positive crossover sign and/or alpha angle >50 deg
based on imaging (CT scan, radiographs and MR
arthrogram)
○Failed 6 weeks of conservative management
▪ Conservative management includes NSAIDs, profile,
patient education and exercise handouts
Exclusion criteria
 Diagnosis of hip osteoarthritis more likely (joint
space narrowing less than 2 mm.)
 Other concurrent systemic disease that may affect
the condition (cancer, rheumatoid arthritis or
systemic arthralgia/arthritis)
 Pending litigation/workmen’s compensation
 Will be moving or relocating within the following
6 months
 Clearing the lumbar spine reproduces the patient’s
hip symptoms
 Pregnancy
 History of prior surgery on the same hip that will be
analyzed in the study
 A formal course of physical therapy within the past
6 months
 Unable to give informed consent to participate in
the study
 Unable to speak or read or write in English
Randomization
Group assignment will be performed using sequentially
numbered opaque sealed envelopes. Once the baseline
examination is complete, an investigator blind to the
randomization process will open the randomization enve-
lope indicating subject’s treatment ground assignment.
Subjects will be randomized into one of two arms (Group
I = Hip Arthroscopy, Group II = Physical Therapy). A
random-number generator will be used to establish
randomization lists prior to the initiation of the study. To
Fig. 1 Proposed Recruitment Flow of Patients
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minimize the risk of predicting the treatment assign-
ment of the next eligible patient, randomization will be
performed in permuted blocks of two or four with ran-
dom variation of the blocking number. Individual
randomization assignments will be concealed according
to the following procedure. The group assignment will
be recorded on a 3.5X5 inch index card. This card will
be folded in half such that the patient’s group assign-
ment will be on the inside of the fold. The folded index
card will then be placed inside the envelope and the en-
velope will be sealed. This will prevent the possibility of
the investigator holding the envelope up to the light
and visualizing the patient’s group assignment through
a sealed yet potentially transparent envelope.
Blinding
Based on the nature of this study, it is not possible to
blind the patient or the clinician providing the interven-
tion to the treatment received. However, the outcomes
assessor will be blinded to treatment group at the
follow-up time points.
Interventions
Both treatment options are standard-of-care interventions.
Their allocation and dosage are described in Table 1.
Hip arthroscopic surgery
The hip arthroscopy will consist of acetabular rim trim-
ming, labral repair or debridement and femoroplasty, all
as indicated based on the surgeon’s clinical judgment
with input from pre-operative imaging, exam findings
and intra-operative findings. Typical surgery time is ap-
proximately 2 h in duration; surgery time may fluctuate
depending on the complexity of the surgery. Hip arth-
roscopy is typically a same-day surgery; however subjects
may require an overnight stay at the discretion of the
orthopedic surgeon. This is standard for how a patient
would receive this intervention outside of the study.
Physical therapy
At the first session, the examiner will perform a standard-
ized clinical examination in order to develop a personalized
impairment-based treatment plan (See Additional file 2).
The six areas that will be tested include: anterior hip mobil-
ity (tested via the FABER position and Thomas test), hip
flexion range of motion (ROM), prone and seated internal
rotation ROM, lumbar mobility in the quadraped rock
position, gluteus medius control in the lateral stepdown
movement and proprioception and lower extremity neuro-
muscular control in the reverse lunge. Based on the specific
impairments (reproduction of the primary hip pain com-
plaint), patient’s supervised physical therapy program will
incorporate joint mobilizations, mobilization with motion,
therapeutic exercise, soft tissue mobility, stretching and
motor control exercises to address these identified impair-
ments (Additional files 3, 4, and 5) . The clinic program will
be reinforced by a home exercise program to address the
specific needs of the patient that will include 8–10 exercises
by the conclusion of the 6 weeks.
Outcome measures
The primary outcome will be the Hip Outcome Score.
Secondary outcome measures will include the iHOT33,
GROC, and NPRS. These will all be taken at baseline, 6,
12, and 24 months. The Self Motivation Inventory and
Pain Catastrophizing Scale will also be taken at baseline
and at 24 months. For our healthcare utilization analysis,
we will collect healthcare utilization and associated costs
that occurred for the duration of the study, and compare
them between groups. We will be using the Military
Health System Data Repository (MDR) for abstraction of
data.
Hip outcome score (HOS)
The HOS is designed to assess higher level activities (i.e.
those required in athletics) and has demonstrated validity
in a study of patients at a mean of 3 years following hip
arthroscopy [18]. Additionally, a 2011 study states that the
HOS has the greatest amount of clinometric evidence (rigor
of rating scales and indexes for the description of clinical
phenomena). Only three published patient-reported out-
come instruments utilized to assess FAI and labral path-
ology use clinometric evidence and the HOS was identified
as the most proven instrument [25].
International hip outcome score (iHOT33)
The iHOT33 is a quality-of-life patient-reported out-
come measure that uses a visual analog scale response
format for young, active patients with hip pathology.
This 33-item questionnaire includes four sections: symp-
toms and functional limitations, sports and recreational
activities, job related concerns and social, emotional and
lifestyle concerns. This outcome measure has shown to
Table 1 Treatment Allocation and Dosage
Intervention Subjects needed Dosage Follow up time (months)
Hip Arthroscopy N = 40 One surgical session (to be followed by
standard post-operative physical therapy
by provider outside of this study)
6, 12, 24
Physical Therapy N = 40 12 sessions with a physical therapist 6, 12, 24
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be reliable; shows face, content and contrast validity and
is highly responsive to clinical change [26].
Global rating of change (GROC)
The GROC will be administered to patients at the initial
data collection, 6 months, 1 and 2 years. The GROC
questionnaire is a common, feasible, and useful method
for assessing short-term outcomes and overall changes
in quality of life [27, 28]. The GROC has a 15-point scale
with a change of positive three points or higher demon-
strating clinically significant improvement in a patient’s
perception of quality of life [27].
Self motivation inventory
The Self-Motivation Inventory is an outcome measure
that was developed to determine level of motivation.
The Self-Motivation Inventory is a 40-item tool that has
been found to measure an individual’s tendency to per-
severe independent of situational reinforcement. It has
also been used to predict successful weight loss and may
correlate with number of sessions attended in weight
loss program [29]. This tool underwent refinement in
1980 with the original 60-item tool being tested in
undergraduate male and females. Items correlating less
than 0.30 were deleted. The final 40-item scale yielded
an exceptionally high internal reliability (α = 0.91) sug-
gesting that a unitary common concept is evident for the
obtained factor structure. The tool is widely used and
has been tested in weight loss and therapeutic exercise
studies [29].
Numeric pain rating scale (NPRS)
A 0–10 numeric pain rating scale (‘0’ indicating no pain,
and ‘10’ worst imaginable pain) will be used to assess
hip pain intensity. Numeric pain scales are known to
have excellent test-retest reliability [30].
Pain catastrophizing scale (PCS)
The PCS is a 13-item patient-report scale developed to
measure the extent to which people catastrophize in re-
sponse to pain. Each item is scored from 0 (‘not at all’)
to 4 (‘all the time’). The PCS is reported as a total score,
with higher scores indicating greater catastrophizing,
and is composed of three sub-scales: Rumination (four
items; e.g. ‘When I am in pain, I keep thinking about
how badly I want the pain to stop’), Magnification (three
items; e.g. ‘When I am in pain, I become afraid that the
pain will get worse’), and Helplessness (six items; e.g.
‘When I am in pain, I feel I can’t go on’) The PCS has
been shown to have high levels of internal consistency
and construct validity [31, 32].
Justification of sample size
Our power analysis was based on the effect size reported
by Martin and colleagues [33] for the Hip Outcome
Score. They reported MCID values of 9 and 6 points for
the Activities of Daily Living (ADL) and sports subscales
respectively [33]. In order to detect a significant change
between groups that is clinically meaningful, we will
need to enroll 20 subjects per group based on the effect
size of the ADL subgroup in the Martin study. This de-
rived minimum sample size will provide us statistical
power of 80 % with an alpha of 0.05. This is the more
conservative analysis. However, the follow-up time
period in the referenced study was only out to 6 months
whereas this study will be out to 2 years. Accounting for
10 % loss to follow-up per year, which often happens in
active duty military populations that deploy or get reas-
signed to multiple posts, we will plan on recruiting 80
subjects.
Data analysis
The primary analysis of effectiveness will be performed
using a linear mixed-effects model that is flexible in ac-
commodating data that is assumed to be missing at ran-
dom. There will be 4 time points for measurement of each
outcome (baseline, 6, 12, and 24 months). Subjects will be
analyzed in the groups that they were originally allocated
to. Sensitivity analyses will be performed to assess the im-
pact of treatment cross over in the results. Descriptive sta-
tistics will be computed to characterize and compare the 2
treatment groups for assessment of baseline heterogeneity.
Distributions of measured variables will be examined visu-
ally with frequency histograms and formally assessed with
Kolmogorov-Smirnov and Shapiro-Wilk statistics to test
the normality assumption. Levene’s test will be used to as-
sess for violations of the homogeneity of variance assump-
tion. Baseline comparability of groups will be tested with
chi-square statistics for categorical variables and with un-
paired t-tests if parametric assumptions are satisfied;
Mann–Whitney U tests otherwise. All statistical tests will
be performed at an alpha level of 0.05.
If one treatment is shown to be superior to the other,
supplemental analyses will be performed by dichotomizing
groups based on minimal clinically important differences
(MCIDs) of 9 for HOS and +3 points for GROC scores.
This will allow computation of absolute risk reduction,
relative risk reduction, and number needed to treat (with
associated 95 % confidence intervals) using failure to ob-
tain clinically meaningful benefit as the event of interest.
Healthcare Utilization will be extracted from the Depart-
ment of Defense Military Health System Data Repository
(MDR) database which is the most commonly used system
operated by TRICARE for research, containing direct and
purchase care data. The amount and type of healthcare
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associated with an FAI-related diagnosis, along with related
cost, will be abstracted for every patient in the study. This
will include diagnostic imaging tests, medications, and spe-
cialty referrals. The amount of utilization for each category
will be compared between groups.
Trial organization and monitoring
The investigative team includes the authors listed in this
protocol. The principal investigator will manage data
flow and perform audits of the procedures, enrollment
and treatment throughout the entire process of this
study. The associate investigators will monitor the data-
collection process and data integrity with periodic evalu-
ation performed continually during the course of the
data-collection phase.
Discussion
The current evidence to support both surgical and con-
servative interventions for femoroacetabular impinge-
ment is based on low-level research. None of these
interventions have been compared in a randomized clin-
ical trial. This is likely due in part to the challenging
methodology associated with conducting trials of this
nature. These treatments are often considered sequential
rather than parallel, meaning that often surgery is not
considered an option until conservative treatment fails
to achieve the desired effect.
Comparative studies of this nature have been con-
ducted successfully in other body regions. Kirkley et. al.
[34] compared arthroscopic surgery and physical therapy
to only physical therapy in patients with moderate-to-
severe knee osteoarthritis. Six of the patients assigned to
surgery did not undergo surgery, and none of the pa-
tients randomized to physical therapy crossed over to
have surgery. In contrast, a study by Katz and colleagues
[35] had much higher cross over rates. They randomized
351 patients with knee osteoarthritis and a meniscus tear
to receive either physical therapy or arthroscopic sur-
gery. At 6 months, 51 (30 %) of the patients randomized
to physical therapy had undergone surgery, while only 9
(6 %) that had been assigned to surgery had not had
their surgery. Weinstein and colleagues [36] conducted
two-tiered study consisting of a prospective cohort tier
and a randomized controlled tier for patients with de-
generative spondylolisthesis and lumbar spinal stenosis.
The randomization tier placed patients into either a
standard decompressive laminectomy or usual nonsurgi-
cal care. Patients were offered their choice of either the
cohort (for those that definitely wanted surgery) or the
randomization between surgery and physical therapy.
There was a cross over rate of approximately 40 % for
each group in the randomization tier.
Crossing over to receive a different treatment than was
originally assigned is a common concern, especially in
pragmatic trials. Although this may not reflect a sterile
outcome from a specific treatment, the importance of ana-
lyzing subjects within the original groups they were ran-
domized to, regardless of cross over, is an important step
to minimize bias, and necessary if trials results are to be
reported in adherence to the CONSORT statement for
transparent reporting of clinical trials [37].
The challenge of recruitment is not limited to patient
preference alone. Clinical equipoise describes the ethical
challenges that healthcare providers face when assigning
patients to various treatment arms of a clinical trial [38].
In this case, if a surgeon believes that the surgical arm is
truly superior, it may pose an ethical dilemma when of-
fering treatment choices to a patient. A study assessing
the clinical equipoise of surgeons faced with clinical sce-
narios that involved randomizing patients to receive op-
erative or non-operative treatment found that 77 % of
the polled surgeons that routinely performed surgery for
FAI were willing to recruit patients into a clinical trial
that included a non-operative arm [39]. Seventy-five per-
cent of the respondents felt that non-operative treat-
ment ≥ 12 months would still be appropriate [39].
Due to the established prevalence of hip pathology,
and the rising rates of surgery for FAI, there is a need to
determine the impact of surgical and non-surgical treat-
ments on long-term clinical results. A comparison of
treatment options for FAI will help guide healthcare pro-
viders in decisions related to optimal effectiveness and
timing of treatment.
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